Want to see AU:MVP full AI Analyst Report?
MVP Stock Chart & Stats
AU$0.46
-AU$0.02(-4.00%)
At close: 4:00 PM EDT
AU$0.46
-AU$0.02(-4.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.77
Previous CloseN/A
Volume529.07K
Average Volume (3M)144.64K
Market Cap
AU$46.75M
Enterprise ValueAU$26.09M
Total Cash (Recent Filing)AU$21.37M
Total Debt (Recent Filing)AU$1.67M
Price to Earnings (P/E)74.1
Beta1.42
Next Earnings
Feb 25, 2027EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding112,658,325
10 Day Avg. Volume120,286
30 Day Avg. Volume144,638
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.80
Price to Sales (P/S)1.05
P/FCF Ratio8.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside117.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$45.95M
Bulls Say, Bears Say
Bulls Say
Pain Management Growth And Market PenetrationStrong Pain Management growth across Europe and Australia indicates expanding demand and improving penetration for Penthrox. Broad volume gains across regions, including hospitals, provide a durable pathway for revenue growth beyond any single customer or geography over the next several quarters.
Conservative Balance Sheet And Improved Cash GenerationVery low leverage gives MVP substantial financial flexibility to fund product development, regulatory work, and targeted geographic expansion without relying heavily on external financing. The sharp improvement in operating and free cash flow also strengthens resilience, although consistency remains important.
Penthrox Regulatory And Evidence-based ExpansionThe expanded European pediatric label materially broadens Penthrox's addressable patient population, while published clinical and economic evidence can support adoption by healthcare providers and payers. These milestones strengthen the product's commercial foundation and support disciplined entry into additional indications and markets.
Bears Say
Thin And Historically Volatile ProfitabilityAlthough MVP has returned to positive earnings, the low net margin leaves limited protection against cost, currency, or demand pressures. The recent history of substantial losses shows that profitability is not yet proven through a full operating cycle, making earnings durability a material concern.
Respiratory Segment ContractionThe Respiratory decline offsets part of the stronger Pain Management performance and leaves group growth more dependent on Penthrox. Continued weakness in this segment could reduce revenue diversification, limit operating leverage, and make consolidated results more sensitive to execution in one primary franchise.
FY2027 Earnings Face Non-recurring Benefits And Cost HeadwindsFY2027 comparisons will be pressured as temporary inventory and working-capital benefits unwind, while amortisation of European registration costs adds a recurring reported expense. Management also cited tariff and supply-chain uncertainty, creating several near-term constraints on earnings conversion.
Medical Developments International Limited News
MVP FAQ
What was Medical Developments International Limited’s price range in the past 12 months?
Medical Developments International Limited lowest share price was AU$0.36 and its highest was AU$0.77 in the past 12 months.
What is Medical Developments International Limited’s market cap?
Medical Developments International Limited’s market cap is AU$46.75M.
When is Medical Developments International Limited’s upcoming earnings report date?
Medical Developments International Limited’s upcoming earnings report date is Feb 25, 2027 which is in 136 days.
How were Medical Developments International Limited’s earnings last quarter?
Medical Developments International Limited released its earnings results on Aug 19, 2026. The company reported AU$0.007 earnings per share for the quarter, beating the consensus estimate of -AU$0.006 by AU$0.013.
Is Medical Developments International Limited overvalued?
According to Wall Street analysts Medical Developments International Limited’s price is currently Undervalued.
Does Medical Developments International Limited pay dividends?
Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of 0.49%. See more information on Medical Developments International Limited dividends here
What is Medical Developments International Limited’s EPS estimate?
Medical Developments International Limited’s EPS estimate is 0.01.
How many shares outstanding does Medical Developments International Limited have?
Medical Developments International Limited has 112,658,325 shares outstanding.
What happened to Medical Developments International Limited’s price movement after its last earnings report?
Medical Developments International Limited reported an EPS of AU$0.007 in its last earnings report, beating expectations of -AU$0.006. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Medical Developments International Limited?
Currently, no hedge funds are holding shares in AU:MVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medical Developments International Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (117.39% Upside)
AU$1.00 (117.39% Upside)
Blogger Sentiment
Bullish
AU:MVP Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.60%
12-Months-Change
Fundamentals
Return on Equity
1.13%
Trailing 12-Months
Asset Growth
-3.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medical Developments International Limited
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
MVP Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(117.39% Upside)
Technical Analysis
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―